ImageneBio, Inc. (IMA) income statement
IMANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 9, 2026Score 6/30
$3.90+0.70 (+21.87%)
Close on Nov 17, 2026Market cap $44.27MP/E –Yield –
ImageneBio, Inc. income statement
Ratios
Latest available, balances at Jun 30, 2026
Profitability, FY2025
- Gross margin
- –
- Operating margin
- -7370.1%
- Net margin
- -6560.5%
- Return on equity, FY2025
- 330.7%
Financial strength
- Current ratio
- 21.47
- Debt to equity
- –
- Debt to assets
- –
- Cash to current liabilities
- 1440.4%
Valuation
- P/E ratio
- –
- Price to sales
- –
- Price to book
- 0.31
- Dividend yield
- –
See a number that looks wrong?